AstraZeneca Completes Aspen Agreement ASTRAZENECA COMPLETES

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Sep 1, 2016 at 2:15 AM

AstraZeneca Completes Aspen Agreement

ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO 01 September 2016 07:00 BST ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO AstraZeneca today announced that it has completed* the commercialisation agreement (https://www.astrazeneca.com/media-centre/press -releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for -anaesthetic-medicines-portfolio-08062016.html) with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company’s financial statements. * With the exception of Ukraine and Zimbabwe, which are subject to separate closing About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS +------------------+-----------+------------------+ | Media Enquiries | | | +------------------+-----------+------------------+ | Neil Burrows | UK/Global | +44 203 749 5637 | +------------------+-----------+------------------+ | Vanessa Rhodes | UK/Global | +44 203 749 5736 | +------------------+-----------+------------------+ | Karen Birmingham | UK/Global | +44 203 749 5634 | +------------------+-----------+------------------+ | Rob Skelding | UK/Global | +44 203 749 5821 | +------------------+-----------+------------------+ | Jacob Lund | Sweden | +46 8　553　260 20 | +------------------+-----------+------------------+ | Michele Meixell | US | +1 302 885 2677 | +------------------+-----------+------------------+ +---------------------+-------------------------------------+------------------ -+ | Investor Relations | | | +---------------------+-------------------------------------+------------------ -+ | UK | | | +---------------------+-------------------------------------+------------------ -+ | Thomas Kudsk Larsen | | +44 203 749 5712 | +---------------------+-------------------------------------+------------------ -+ | Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 | +---------------------+-------------------------------------+------------------ -+ | Nick Stone | Respiratory & Autoimmunity | +44 203 749 5716 | +---------------------+-------------------------------------+------------------ -+ | Henry Wheeler | Oncology | +44 203 749 5797 | +---------------------+-------------------------------------+------------------ -+ | Christer Gruvris | Infection & Neuroscience | +44 203 749 5711 | +---------------------+-------------------------------------+------------------ -+ | US | | | +---------------------+-------------------------------------+------------------ -+ | Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 | +---------------------+-------------------------------------+------------------ -+ | Mitchell Chan | Oncology | +1 240 477 3771 | +---------------------+-------------------------------------+------------------ -+ | Toll-free | | +1 866 381 7277 | +---------------------+-------------------------------------+------------------ -+ -ENDS-

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tradier Brokerage Data Breach Sparks Legal Probe

Data Breach Drama Hits Tradier Brokerage Picture a broker-dealer like Tradier Brokerage, out in Charlotte, getting its customers' details hanging out there for the world to see. A calamity, courtesy of a cyberattack on their third-party vendor, Etna Software Corp. And we're talking Social Security numbers, tax IDs—emails across Texas and Massachusetts were popping up...

SAMILBIO Gambles on 'Chaeyun' Launch With November Events

Can SAMILBIO's New Products Make a Splash? In a world where skincare is more competitive than a hot dog stand outside a vegan festival, here comes SAMILBIO with their latest offerings. Launching a whitening cream and an acne-fighting gel under the 'Chaeyun' brand, this company isn't just sticking to digital—it's diving into face-to-face consumer interaction. I mean,...

Fluence Energy Faces Class Action Amid $3B Wipeout

The Fluence Fiasco: From Optimism to Legal Battles One minute you're riding high on promises, the next you're grappling with losses that could sink a ship. Fluence Energy (NASDAQ: FLNC) is learning this harsh lesson, as its shareholders eye a nasty $3 billion nosedive and a fresh securities class action lawsuit to boot. Imagine thinking you're poised to tap into an...

InsCorp's Steady Q3 Climb Mirrors Strategic Focus

Riding the Revenue Wave Now we're talking about a bank knowing their business—InsCorp, Inc. recently flaunted a 12% year-on-year revenue bump for 3Q26, a testament to a strategy that's clearly sticking. Still, while those numbers are nice and shiny, the detailed breakdown shows earnings per share (EPS) barely budged from last quarter, coming in at $0.73, just a hair...

KSAT and MSU Boost Lunar Network for Space Growth

Breaking Ground in Space: KSAT and MSU Join Forces Here's a cosmic twist in the world of satellite communications: KSAT and Morehead State University (MSU) are teaming up to expand the lunar frontier. This ain't small potatoes; it's a strategic handshake aimed at beefing up KSAT's lunar network. They're set to amplify support for the growing hunger in deep space...

How Dental Cleaning Frequency Boosts Oral Health

Cleaning Up Confusion on Dental Visits Never thought I'd be waxing poetic about gum health, but here we are. You know what they say, ain't no business like show business—and today's show is all about the pearly whites context, courtesy of Dr. Calvin Despain over in Moses Lake, Washington. Apparently, keeping that grin free from plaque isn't as simple as a quick brush...

HK Boosts Oversight of Building Repairs Post-Blaze

Big Moves After a Tragic Fire Hong Kong's revamping its approach to building maintenance and oversight, clearly in reaction to the horrific Wang Fuk Court blaze last year. That fire didn't just leave scars; it blew open glaring gaps in the city's oversight of building repairs. The government's now jumping into action by launching a raft of measures aimed at preventing...

Gildan Faces Lawsuit: Allegations of Revenue Inflations

Gildan's Revenue Magic Trick or Corporate Roulette? Imagine turning on the news just as Gildan's stock takes a freefall dive. June 16, 2026, didn't just mark another dip on the charts for NYSE: GIL; it sent investors tripping over phone cords as shares plummeted a whopping 18.75%. That's not your everyday market swing, folks. Behind this dramatic drop looms a hefty class...

Class Action Looms Over Tenax Therapeutics Investors

Shareholders in the Crosshairs Every once in a while, the market serves up a cold dish of reality, and folks owning Tenax Therapeutics (NASDAQ:TENX) are facing just that. A class action is casting a long shadow, targeting those who bought in between November 13, 2023, and August 7, 2026. It's the kind of headache that no investor wakes up hoping for. The Allegations: When...

ServiceTitan Faces Investor Fury: Revenue Surprise

A Crippling Blow for ServiceTitan Investors When you're in the investing game long enough, you start to recognize the scent of trouble before it even hits the fan. In the case of ServiceTitan, Inc. (NASDAQ: TTAN), the smell came wafting in strong when the stock took a nosedive on September 9, 2026. Investors were left clutching their portfolios with bewilderment as shares...